The Claim
Semaglutide treatment in obese mice reduces gastrocnemius muscle mass by approximately 15–20% without impairing maximal isometric force under steady-state conditions, indicating a dissociation between muscle size and strength during pharmacologic weight loss.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice, semaglutide treatment reduces gastrocnemius muscle mass by 15–20% while leaving maximal isometric muscle force unchanged during steady-state conditions.
See the scientific wording
Semaglutide treatment in obese mice reduces gastrocnemius muscle mass by approximately 15–20% without impairing maximal isometric force under steady-state conditions, indicating a dissociation between muscle size and strength during pharmacologic weight loss.
When the body receives a signal that reduces appetite, it enters a low-nutrient state that slows down muscle repair and causes muscle fibers to shrink. At the same time, a chemical called PGE2 activates a pathway that keeps muscle cells able to generate strong contractions, so strength stays normal even as muscle gets smaller.
What the research says
1 studySemaglutide made the mice’s muscles smaller after injury, but their muscles still stayed strong — meaning you can lose muscle size without losing strength. This matches the claim that muscle can shrink without getting weaker.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.